新型冠状病毒感染与自身免疫异常:间质性肺疾病的发病机制共性与治疗策略探索  

COVID-19 and autoimmune dysregulation:exploring common mechanisms and treatment strategies in interstitial lung disease

作　　者：张泽 周敏[1] Zhang Ze;Zhou Min(Department of Pulmonary and Critical Care Medicine,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院呼吸与危重症医学科,上海200025

出　　处：《中华结核和呼吸杂志》2024年第6期571-575,共5页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：上海市2023年度生物医药定向应急攻关项目(23DX1900300)

摘　　要：新型冠状病毒感染(COVID-19)是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染引发的以急性肺部损伤为主要症状的疾病,影像上多见双肺弥漫性间质性病变,患者常伴有类似于自身免疫性疾病的临床表现,与自身免疫相关的间质性肺疾病在影像变化及治疗和血清学等方面存在诸多共性。自身免疫异常与新冠病毒感染后肺纤维化亦存在关联。本文就新冠病毒感染导致自身免疫异常的发病机制、临床表现、治疗药物等方面的研究进展进行综述。COVID-19 is caused by the infection of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and manifests primarily as acute lung injury with diffuse interstitial lung disease evident in imaging.Patients often present with clinical features similar to those of autoimmune diseases and share imaging,treatment and serological similarities with autoimmune-related interstitial lung diseases.The association between autoimmune abnormalities and post-COVID-19 pulmonary fibrosis is also recognized.This article provided a comprehensive review of the pathogenic mechanisms,clinical manifestations,and therapeutic interventions associated with autoimmune abnormalities induced by SARS-CoV-2 infection.

关 键 词：冠状病毒感染 自身免疫 肺纤维化 血清学 严重急性呼吸综合征冠状病毒 策略探索 共性 

分 类 号：R511[医药卫生—内科学] R563[医药卫生—临床医学]